论文部分内容阅读
本文报告鞘内注射巴氯芬(ITB)用于3例僵人综合征(SMS)患者的双盲安慰对照试验,并做了临床和电生理的加强监护。 本组患者均为原有治疗无效或出现副作用者。3例的病史分别为4年、6年和10年。均符合SMS的临床和电生理诊断标准。全部患者的抗谷氨酸脱羧酶抗体均阳性。给药方法:第一天鞘内注射巴氯芬50μg安慰剂,然后根据患者对50μg给药的反应和医生观察结果,再给予巴氯芬75μg或100μg鞘内注射,并与安慰剂作对照。此后分别进行患者自我评
This article reports the intrathecal baclofen (ITB) administered in a double-blind, placebo-controlled trial of 3 patients with stifled human syndrome (SMS) and has intensive clinical and electrophysiological monitoring. This group of patients are invalid or the original treatment of side effects. The history of 3 cases were 4 years, 6 years and 10 years respectively. All meet the SMS clinical and electrophysiological diagnostic criteria. Anti-glutamic acid decarboxylase antibodies were positive in all patients. Methods of administration: The first day of intraperitoneal injection of baclofen 50μg placebo, and then according to the patient’s response to 50μg administration and the doctor’s observation, then given baclofen 75μg or 100μg intrathecal injection and placebo for control. Since then, patient self-evaluation